Theramex has opted out of the U.K.’s self-regulatory program for pharma marketing after being found to have brought discredit on the industry twice in quick succession.
New data build case for Roche’s oral BTK drug for MS
Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

